These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18442866)

  • 1. A novel mathematical model quantifying drug release from lipid implants.
    Siepmann F; Herrmann S; Winter G; Siepmann J
    J Control Release; 2008 Jun; 128(3):233-40. PubMed ID: 18442866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms controlling protein release from lipidic implants: effects of PEG addition.
    Herrmann S; Winter G; Mohl S; Siepmann F; Siepmann J
    J Control Release; 2007 Apr; 118(2):161-8. PubMed ID: 17275943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants.
    Herrmann S; Mohl S; Siepmann F; Siepmann J; Winter G
    Pharm Res; 2007 Aug; 24(8):1527-37. PubMed ID: 17380261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug release from extruded solid lipid matrices: theoretical predictions and independent experiments.
    Güres S; Siepmann F; Siepmann J; Kleinebudde P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):122-9. PubMed ID: 22008146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug release mechanisms of compressed lipid implants.
    Kreye F; Siepmann F; Siepmann J
    Int J Pharm; 2011 Feb; 404(1-2):27-35. PubMed ID: 21055453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled release implants based on cast lipid blends.
    Kreye F; Siepmann F; Zimmer A; Willart JF; Descamps M; Siepmann J
    Eur J Pharm Sci; 2011 May; 43(1-2):78-83. PubMed ID: 21463679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling drug release from PVAc/PVP matrix tablets.
    Siepmann F; Eckart K; Maschke A; Kolter K; Siepmann J
    J Control Release; 2010 Jan; 141(2):216-22. PubMed ID: 19737588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled diffusional release of dispersed solute drugs from biodegradable implants of various geometries.
    Collins R; Paul Z; Reynolds DB; Short RF; Wasuwanich S
    Biomed Sci Instrum; 1997; 33():137-42. PubMed ID: 9731349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharma-robust design method to investigate the effect of PEG and PEO on matrix tablets.
    Park JS; Shim JY; Nguyen KV; Park JS; Shin S; Choi YW; Lee J; Yoon JH; Jeong SH
    Int J Pharm; 2010 Jun; 393(1-2):79-87. PubMed ID: 20399261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of drug solubility on in vitro availability rate from suppositories with polyethylene glycol excipients.
    Realdon N; Ragazzi E; Ragazzi E
    Pharmazie; 2001 Feb; 56(2):163-7. PubMed ID: 11234347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model for the drug release from a polymer matrix tablet--effects of swelling and dissolution.
    Borgquist P; Körner A; Piculell L; Larsson A; Axelsson A
    J Control Release; 2006 Jul; 113(3):216-25. PubMed ID: 16797098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights.
    Wu N; Wang LS; Tan DC; Moochhala SM; Yang YY
    J Control Release; 2005 Feb; 102(3):569-81. PubMed ID: 15681080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical analysis of release kinetics of coated tablets containing constant and non-constant drug reservoirs.
    Zhou Y; Chu JS; Li JX; Wu XY
    Int J Pharm; 2010 Jan; 385(1-2):98-103. PubMed ID: 19879936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants.
    Li C; Cheng L; Zhang Y; Guo S; Wu W
    Int J Pharm; 2010 Feb; 386(1-2):23-9. PubMed ID: 19895876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends.
    Cheng L; Lei L; Guo S
    Int J Pharm; 2010 Mar; 387(1-2):129-38. PubMed ID: 20005928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.
    Avdeef A; Kansy M; Bendels S; Tsinman K
    Eur J Pharm Sci; 2008 Jan; 33(1):29-41. PubMed ID: 17983735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling drug release from hot-melt extruded mini-matrices with constant and non-constant diffusivities.
    Verhoeven E; Siepmann F; De Beer TR; Van Loo D; Van den Mooter G; Remon JP; Siepmann J; Vervaet C
    Eur J Pharm Biopharm; 2009 Oct; 73(2):292-301. PubMed ID: 19549569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of drug transport properties by multicomponent diffusion in surfactant aqueous solutions.
    Zhang H; Annunziata O
    Langmuir; 2008 Oct; 24(19):10680-7. PubMed ID: 18717577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants.
    Sax G; Winter G
    J Control Release; 2012 Oct; 163(2):187-94. PubMed ID: 22964391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.